TY - JOUR
T1 - Slow but Steady Wins the Race
T2 - Dissimilarities among New Dual Inhibitors of the Wild-Type and the V27A Mutant M2 Channels of Influenza A Virus
AU - Barniol-Xicota, Marta
AU - Gazzarrini, Sabrina
AU - Torres, Eva
AU - Hu, Yanmei
AU - Wang, Jun
AU - Naesens, Lieve
AU - Moroni, Anna
AU - Vázquez, Santiago
N1 - Funding Information:
M.B.-X. thanks the Institute of Biomedicine of the Universitat de Barcelona (IBUB) for a Ph.D. grant. We thank the Spanish Ministerio de Ciencia e Innovación (FPU fellowship to E.T.; grant SAF2014-57094-R to S.V.). L.N. acknowledges financial support from the Geconcerteerde Onderzoeksacties (GOA/15/ 019/TBA) and technical assistance from W. van Dam. J.W. acknowledges the support from NIH grant AI119187. We thank Prof. W. F. DeGrado for his expert advice
Publisher Copyright:
© 2017 American Chemical Society.
PY - 2017/5/11
Y1 - 2017/5/11
N2 - New insights on the amantadine resistance mechanism of the V27A mutant were obtained through the study of novel, easily accessible 4-(1- and 2-adamantyl)piperidines, identified as dual binders of the wild-type and V27A mutant M2 channels of influenza A virus. Their antiviral activity and channel blocking ability were determined using cell-based assays and two-electrode voltage clamp (TEVC) technique on M2 channels, respectively. In addition, electrophysiology experiments revealed two interesting findings: (i) these inhibitors display a different behavior against the wild-type versus V27A mutant A/M2 channels, and (ii) the compounds display antiviral activity when they have kd equal or smaller than 10-6 while they do not exhibit antiviral activity when kd is 10-5 or higher although they may show blocking activity in the TEV assay. Thus, caution must be taken when predicting antiviral activity based on percent channel blockage in electrophysiological assays. These findings provide experimental evidence of the resistance mechanism of the V27A mutation to wild-type inhibitors, previously predicted in silico, offer an explanation for the lack of antiviral activity of compounds active in the TEV assay, and may help design new and more effective drugs.
AB - New insights on the amantadine resistance mechanism of the V27A mutant were obtained through the study of novel, easily accessible 4-(1- and 2-adamantyl)piperidines, identified as dual binders of the wild-type and V27A mutant M2 channels of influenza A virus. Their antiviral activity and channel blocking ability were determined using cell-based assays and two-electrode voltage clamp (TEVC) technique on M2 channels, respectively. In addition, electrophysiology experiments revealed two interesting findings: (i) these inhibitors display a different behavior against the wild-type versus V27A mutant A/M2 channels, and (ii) the compounds display antiviral activity when they have kd equal or smaller than 10-6 while they do not exhibit antiviral activity when kd is 10-5 or higher although they may show blocking activity in the TEV assay. Thus, caution must be taken when predicting antiviral activity based on percent channel blockage in electrophysiological assays. These findings provide experimental evidence of the resistance mechanism of the V27A mutation to wild-type inhibitors, previously predicted in silico, offer an explanation for the lack of antiviral activity of compounds active in the TEV assay, and may help design new and more effective drugs.
UR - http://www.scopus.com/inward/record.url?scp=85019197215&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85019197215&partnerID=8YFLogxK
U2 - 10.1021/acs.jmedchem.6b01758
DO - 10.1021/acs.jmedchem.6b01758
M3 - Article
C2 - 28418242
AN - SCOPUS:85019197215
VL - 60
SP - 3727
EP - 3738
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
SN - 0022-2623
IS - 9
ER -